Nothing can slow Alzheimer's, only ease the symptoms
The old claim turned out to be wrong and was rejected by evidence.
TaughtThere is no way to slow or stop Alzheimer's disease. The available drugs treat symptoms like memory loss and agitation for a while, but the underlying decline is unstoppable.
NowIn 2023 the FDA fully approved lecanemab (Leqembi), an antibody that clears amyloid from the brain and modestly slows cognitive decline, the first treatment shown to change the course of the disease rather than only its symptoms.
What actually happened
For decades the amyloid hypothesis, that sticky beta-amyloid plaques drive Alzheimer's, produced one failed drug after another, to the point where many researchers doubted it. Earlier antibodies either did not work or were approved on contested evidence.
Lecanemab's large phase-3 trial was the turn: over 18 months it slowed decline by roughly 27% compared with placebo, and the FDA granted full approval in July 2023. That is genuinely disease-modifying, and it is also genuinely modest, a matter of months of delayed decline, not a cure and not a reversal.
The caveats belong in the same breath as the result: the benefit is small, the drug requires regular infusions and MRI monitoring, and it can cause brain swelling and bleeding. Nobody should read this as "Alzheimer's is treatable now." What changed is narrower and still real, the flat claim that nothing can touch the disease itself is no longer true.
Newsletter
Get new weekly revisions
Sources
Who was taught this
Still standard through 2023, so anyone who finished school between 1950 and 2023 learned the earlier version.